BNTX · NASDAQ
Average $126.58 (+38.8% upside)
The latest rating actions, newest first
| Firm | Date | Action | Rating |
|---|---|---|---|
| Canaccord Genuity | Oct 14, 2026 | Maintains | Buy |
| Morgan Stanley | Oct 7, 2026 | Maintains | Overweight |
| BMO Capital | Sep 8, 2026 | Downgrade | Outperform → Market Perform |
| Canaccord Genuity | Aug 31, 2026 | Maintains | Buy |
| Citigroup | Aug 5, 2026 | Maintains | Buy |
| Evercore ISI Group | Aug 5, 2026 | Maintains | Outperform |
| Morgan Stanley | Jul 8, 2026 | Maintains | Overweight |
| UBS | May 27, 2026 | Upgrade | Neutral → Buy |
| Bernstein | May 22, 2026 | Initiates | Market Perform |
| Canaccord Genuity | May 6, 2026 | Maintains | Buy |
Updated Sep 15, 2026
BioNTech is a promising company with a strong pipeline of innovative oncology drugs and a successful and in-demand covid vaccine. Financially, the company is projected to have a firm value of $33B and has potential for future partnerships and market uptake. While risks do exist, BioNTech's advancements in the field of immunotherapy and its positive clinical trial data make it a strong investment opportunity with a potential upside reflected in the price target of $130 per share.
BioNTech is facing several key risks, including: (1) competition from other biotech companies with similar products or pipelines; (2) potential failure of their cancer therapeutics and vaccines in clinical trials; (3) failure to advance their other programs in a timely manner, leading to possible commercial and regulatory risks and long-term dilution for investors. Additionally, their partnerships and potential for mergers and acquisitions may bring about its own set of risks.
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.
